Publication | Open Access

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Neurological DisorderPhase 2BClinical TrialsPlacebo-controlled TrialPharmacotherapyNeurologyMultiple SclerosisMedicineNeuroimmunologyNovel Therapy